Top Pharmaceuticals

2009 Top 20 Pharmaceutical Companies Report

They don’t call them “Big Pharma” for nothing! Several of the industry’s biggest players decided to get bigger via M&A this year, which means next year’s ranks are going to feature at least three new players, once Wyeth and Schering-Plough are swallowed up and Roche moves over to the Top Biopharma ranks. And I do mean top!

It’s a good thing my “Pharm System” has a whole crop of new companies to move into the ranks — you're on deck, Gilead! — but how will all these mergers and consolidations affect contract service providers? Columnist Michael Martorelli has some thoughts on the subject in this issue, but pharma companies remain quiet about how they’ll reconcile their internal mega-networks with their outsourcing strategies. So stay tuned . . .
—Gil Y. Roth, Editor

Top 20 Pharmaceutical Companies
01 Pfizer $44,174
02 Sanofi-Aventis $40,562
03 GlaxoSmithKline $37,810
04 Novartis $35,647
05 AstraZeneca $30,677
06 Merck $25,901
07 Johnson & Johnson $24,567
08 Roche $23,624
09 Eli Lilly & Co. $19,285
10 Bristol-Myers Squibb $17,715
11 Wyeth $17,391
12 Schering-Plough $16,534
13 Abbott Laboratories $16,013
14 Takeda $13,841
15 Bayer Schering $13,803
16 Boehringer Ingelheim $13,405
17 Teva* 10,482
18 Astellas* $9,646
19 Daiichi-Sankyo* $7,900
20 Eisai* $7,612

Based on 2008 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.
For the pipeline and patent expiry info, download the PDFs of the profiles, available within each company's page.

* PDF profiles only available for companies 17-20


Contributors
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Bayer-Schering, by Kristin Brooks.

Thế nhưng bước sang đầy năm 2010, một báo cáo khác cho thấy có sự thay đổi:

26.03.2010 18:16
FACTBOX-The 20 largest pharmaceutical companies

March 26 (Reuters) - The following is a list of the top 20

pharmaceutical companies, ranked by global prescription drug

sales for the 12 months through September 2009, according to

pharmaceutical market research company IMS Health Inc.

The chart shows sales -- in billions of U.S. dollars -- and

percent change over the period. The data does not include the

results from mega acquisitions by Pfizer and Merck , as their deals for Wyeth and Schering-Plough,

respectively, were completed in the fourth quarter.

A year after a wave of mega-mergers shook up the

pharmaceutical industry, the remaining big drugmakers most

often mentioned as takeout or merger candidates appear set to

go it alone as they edge toward their patent cliffs.


Company Sales (billion US$) % change

1) Pfizer $41.7 (0.

2) Novartis $36.7 + 7.0

3) Sanofi-Aventis $35.1 + 3.3

4) GlaxoSmithKline $34.3 (3.4)

5) AstraZeneca $33.2 + 7.8

6) Roche $31.3 + 8.6

7) Johnson&Johnson $26.9 (6.6)

Merck&Co $25.0 (4.1)

9) Eli Lilly $19.6 + 8.3

10) Abbott $19.4 + 5.5

11) Teva $15.7 + 12.3

12) Bayer $15.4 + 3.9

13) Wyeth $14.8 (2.3)

14) Amgen $14.8 (3.1)

15) Boehringer $14.6 + 10.4

16) Takeda $14.4 + 2.1

17) Bristol-Myers $14.2 + 5.8

18) Schering-Plough $13.1 + 4.3

19) Daiichi Sankyo $8.5 + 3.1

20) Novo Nordisk $8.2 + 11.6


(Source: IMS Health)

Cập nhật tình hình doanh số các công ty Dược 2014 nhé:

1. J&J, US: 71,3 Bio USD
2. Novartis, Switzerland: 60.9
3. Roche, Switzerland: 52.4
4. Pfizer, U:S 51.6
5. Sanofi, France: 45.8
6. Merck, US: 44
7. GSK, UK: 43.9
8. AZ, UK: 27.2
9. Eli Lilly, US: 23.1
10. Abbott Lab, US: 21.8

http://www.statista.com/statistics/272717/top-global-biotech-and-pharmaceutical-companies-based-on-revenue/

Vậy là Novartis sales hàng thứ 4 nhưng lợi nhuận hàng thứ 2, còn Pfizer tuy sales rất lớn nhưng lợi nhuận lại hàng thứ 4